CLL is usually diagnosed when the circulating B lymphocytes exhibit the characteristic immunophenotyping pattern of CD5+, CD23+, FMC7-, CD79b-/CD22- and a weak expression of surface membrane immunoglobulin (SmIg). This evidence concerns the gene CD22 and B-cell chronic lymphocytic leukemia.